Select Page

This study covers the market dynamics and trends in major countries that are expected to influence the current market scenario and future status of the Global In-Vitro diagnostics Market over the forecast period.

Market Report Titled “In-Vitro Diagnostics Market Research Report – Forecast to 2023″ is a Specialist Examination Report Explores the Market by Research Methodology, Segmentation, Key Players, and Major Region Globally.

In-Vitro Diagnostics Market overview 

In-Vitro diagnostics (IVD) is used for detecting infections and diseases by taking the specimen from the human body for curing diseases or its sequelae. The in vitro diagnostics products include products such as reagents, instruments, or any system that is used for the diagnosis of diseases. The In-Vitro diagnostics has gained a quick momentum as a modern medical diagnostic system.

IVD relies on the several types of laboratory-based tests that perform biological specimens. There has been a development of better solutions for disease prevention, treatment and management that help in in-vitro diagnostics. There has been an increase in the incidence of chronic and infectious diseases and the growth in the geriatric population is driving the IVD market.

The global in-vitro diagnostics market report presents the trend in the global market with the modern testing and diagnostic activities that are conducted using IVD. The report points towards the valuation of USD 69,200 million in the year 2017. It shows that the market will remain positive for some years to come. There have been advances in molecular diagnostics and the increasing acceptance of the medicine has expanded using the in-vitro diagnostic applications.

In-Vitro Diagnostics Market Companies Covered

  • Thermo Fisher Scientific
  • Abbott Laboratories
  • DiaSorin S.p.A
  • Becton Dickinson and Company
  • Sysmex Corporation
  • BioMérieux S.A
  • Qiagen N.V.
  • Grifols S.A
  • Ortho Clinical Diagnostics
  • F. Hoffmann-La Roche AG
  • Siemens AG
  • Bio-Rad Laboratories Inc.
  • Danaher Corporation

In-Vitro Diagnostics Market segmentation

The global in-vitro diagnostic market report offers a comprehensive segmental analysis of the global market. So, based on the global products and services, the global market can be split into:

  • Instruments
  • Reagents and kits
  • Data management software

Based on the technology, the global in-vitro diagnostic market can be divided into:

  • Clinical chemistry
  • immunoassay/immunochemistry
  • Microbiology
  • Molecular diagnostics
  • Hematology

As per the application, the global in-vitro diagnostic market can be classified into:

  • Non-infectious diseases
  • Infectious diseases

Lastly, according to the end-users, the global in-vitro diagnostics market can be divided into:

  • Laboratories
  • Hospitals
  • Academic institutes

Increasing number of public and private diagnostic centers is expected to fuel the growth of the global market during the aforementioned period. In addition to this, the spurring micro-size diagnostics centers in the developing economies is opening new ways and windows for the growth of the IVD industry.

In-Vitro Diagnostics Market Regional analysis

The geographical description shows that North America holds the largest market share with the favourable government regulations, well-established diagnostic infrastructure, and the various technological advancements in the in-vitro field, with the presence of key players that make this region the most dominant. The IVD market size is based on a comprehensive analysis of the various applications and development in the global industry. A qualitative study has been done on the basis of the innovative products that help to facilitate the strategic business planning in the global in-vitro diagnostics market.

Asia-Pacific market provides lucrative opportunities for the key players with the improvement in healthcare infrastructure.

In-Vitro Diagnostics Industry news 

Abbot has announced the launch of a lab-based serology blood test for detecting the presence of the antibody that tells whether the person has COVID-19 or not. This test will be available for ARCHITECT i1000SR and i2000 laboratory instruments. This company has done its third test for coronavirus after the m2000 molecular lab systems and the ID NOW molecular point-of-care device.